http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020021378-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d2809dd5a1e19e9258bca71b385ead8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2019-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_386aead57b69a73afd0b40c21391fc5e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c6179fc81f307e0fee537dd79a59253 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13cf443444ee7ec44fd56e2f011b44a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ea00250982dbda524c1cb2684c6e325 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_940cc57bb6a7e20fa054b333c4050a0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51bfafc2fa3a2606241f1cfc44f4d8f6 |
| publicationDate | 2020-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020021378-A1 |
| titleOfInvention | 1,3,8-triazaspiro compounds and their use as medicaments for the treatment of reperfusion injury |
| abstract | The present invention relates to a 1,3,8-triazaspiro compound of Formula (I), wherein A is -CH2, -SO2 -, -NH-CO-, -NH-CS- or -CO-; the dashed line represents a single or double bond; R1 is a substituent selected from (C1-C3) alkyl, phenyl, thienyl and cyclohexyl, said substituent being optionally substituted by halogen or (C1 -C3) alkyl; and R2 is a substituent selected from H, (C1-C3) alkyl, (C1-C3) alkoxy, -CF3 and halogen; and wherein, when the dashed line is a double bond, A is -CH2 - and R1 is phenyl, or a pharmaceutically acceptable salt thereof for use in the treatment of reperfusion injury diseases. The 1,3,8-triazaspiro compound of the invention is a selective inhibitor of the C subunit of the F1/Fo-ATP synthase complex and a modulator of the mitochondrial permeability transition pore activity in mammalian cells and tissues, in the treatment of reperfusion injury diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022035902-A1 |
| priorityDate | 2018-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 273.